“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01% Tazarotene 0.045% Lotion”. 2020. SKIN The Journal of Cutaneous Medicine 4 (6): s79. https://doi.org/10.25251/skin.4.supp.79.